1. Why Drug Patent Portfolio Management Determines Who Wins — and Who Exits {#1} Pharmaceutical R&D is one of the […]

Executive Summary Biologics account for roughly 2% of U.S. prescriptions but consumed 38-40% of total pharmaceutical spending in 2023. In

Why Pharmaceutical Patent Searching Is a Different Discipline Drug patent analysis sits at the intersection of medicinal chemistry, patent law,

Part 1: The True Price of Innovation — The Multi-Layered Cost of a Drug Patent Beyond the Filing Fee: The

Executive Summary The patent is the fundamental unit of value in the pharmaceutical industry. A single compound patent on a

Part I: Why This Matters — The Stakes of Drug Patent Intelligence The Numbers Behind a Bad Search The Tufts

A deep-dive analysis for pharma/biotech IP teams, R&D leads, and institutional investors. Introduction: How a Single Negotiation Rewires a Drug’s

Why the Cheapest Generic Manufacturer Usually Loses The dominant assumption inside generic pharma for the past three decades has been

1. Why This Analysis Exists: The $234 Billion Question Nobody Is Answering Precisely Between 2025 and 2034, 118 biologic medicines